Ascletis pulls in $100 mln Series B
Ascletis, a developer of treatments for liver diseases, has closed $100 million in Series B financing. C-Bridge Capital led the round with participation from other backers that included QianHai Equity Investment FOF, FOCUS Media Jiangnanchun Foundation, WTT Investment, Goldman Sachs and Tasly Pharmaceutical.
4 January 2017•1 min read
